Background Cachexia has significant impact on the patients' quality of life and prognosis.
Introduction
Cancer cachexia is a recognized problem in the clinical setting of patients suffering from malignant cancer. It is well known to be associated with increased mortality 1 and decreased well-being of patients. 2 Therapies to stop or even reverse the loss of body weight and muscle mass-which are the hallmarks of cancer cachexia-are lacking 3 ; hence, cancer cachexia is an area of unmet medical need and is hence of great research interest.
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What is less known is that the prevalence of cancer cachexia is relatively low in the general population, compared to common afflictions. This is very relevant for today's research efforts because both the USA and the European Union (EU) have implemented special clinical development rules for what are called 'orphan diseases'. Thereby, both the USA and EU have promoted research into these fields and supported the development of new therapies for these relatively rare diseases. To our knowledge, published evidence has not been available examining whether cancer cachexia should be considered an orphan disease. Therefore, a significant discussion point in any such research context is the actual number of patients who might benefit from new treatment approaches. We therefore wish to address the question of whether cancer cachexia associated with various cancer types, complicating the major cancer subtypes prevalent in developed countries, could be classified as a collection of orphan diseases, based on the available evidence of the number of patients affected.
In the USA, with ca. 319 million inhabitants in 2014, 5 any illness affecting less than 200 000 people is considered to be an orphan disease (as defined by the 'rare disease act of 2002'). 6 In the EU, presently consisting of 28 countries with ca. 505 million inhabitants in 2013, 7 the limit to establish the presence of an orphan disease is 5 per 10 000 people (as defined by the European Medicines Agency) 8 -amounting to a cut-off at 255 000 people for the EU as a whole.
Methods and results
The aim of this analysis was to estimate the number of patients currently suffering in the USA and EU from cachexia complicating both the common cancer types and other specific cancer types where cachexia is known to be a frequent complication. We therefore needed three variables: (i) the prevalence of each cancer type, (ii) the percentage of such patients that are at risk to develop cachexia, and (iii) the prevalence of cachexia in all patients at risk ( Figure 1 ).
Prevalence of cancer entities
In oncologic research, most commonly the 5-year prevalence is used to show the burden of different cancer entities. This is the number of patients who have developed any type of cancer in previous 5 years and who are still alive (at the time of assessment). At the same time, this number does not reveal whether the patient is still suffering from the condition or in fact has actually already been cured. Numbers for the total prevalence of individual cancer types (the proportion of the population with cancer at any time during their lifetime, or 'lifetime prevalence') are not published in EU, in an effort not to stigmatize patients that have been cured of cancer, but these data are available for the USA. These total prevalence data from the USA should be used with some caution, because an unknown proportion of these patients may have already been cured (or be in complete remission). To present the complete picture on both total and 5-year prevalence for both regions, the latest available data for the USA from 2014 ( Table 1  9 ) were used to estimate the total prevalence estimates for the EU in 2013 in Table 2 , 9,10 using the same ratios that were observed between 5-year prevalence and total prevalence in the USA, based on the working assumption that expected total prevalence rates between these two populations would be similar. In both tables, we analysed the top-10 cancer types with the highest prevalence overall and four additional cancer types that are known to be frequently associated with cancer cachexia, namely, head and neck cancer, gastric cancer, liver cancer, and pancreatic cancer. The resulting 14 cancer types selected for analysis represent about 85% of all cancer cases. Of the two prevalence estimates, total and 5 years, the more relevant 5-year prevalence of each cancer type was used in the calculations described below. The 5-year prevalence represents the ongoing burden of each cancer in the USA and EU more accurately and is less influenced by patients who are often considered cured after 5 years of follow-up. In simple terms, this methodology estimates the prevalence of each cancer type after exclusion of likely long-term survivors, thereby more accurately defining the population most likely to be at risk of cachexia. Orphan disease status of cancer cachexia: systematic review
Prevalence of cachexia
For this systematic review, we searched in PubMed to identify clinical studies that assessed the prevalence of cachexia in at least 50 cancer patients at risk, considering articles from inception to 31 January 2018 ( Figure 2 ). Our search algorithm was defined as 'cachexia OR weight loss OR malnutrition AND (cancer OR prostate cancer OR breast cancer OR colorectal cancer OR melanoma OR endometrial cancer OR thyroid cancer OR urinary bladder cancer OR non-hodgkin lymphoma OR lung cancer OR kidney and renal pelvis cancer OR head and neck cancer OR gastric cancer OR liver cancer OR pancreatic cancer) AND (frequency OR epidemiology OR prevalence OR estimate)'. We excluded all reviews, clinical trials, case reports, animal studies, studies in children aged <18 years, not published in English, less than 50 patients, lacking data on cachexia, or weight loss prevalence in specific cancer entities. Studies reporting the prevalence of either cachexia or wasting disease in any of the top-10 most prevalent cancer types plus 4 other selected cancer types known to be particularly often complicated by cachexia were screened and included in this analysis. Senior colleagues were interviewed to find additional relevant papers in areas were few or no reports of interest could be identified.
Altogether, we identified 21 studies published between 1980 and 2017 and reporting on 31 047 cancer patients as shown in Table 3. 11-31 These studies provided acceptably reliable data for all of the 14 cancer entities selected for analysis. Depending on the diagnosis, results for 500 to 4900 patients were available. Only for melanoma were fewer patients reported upon, because cachexia in melanoma patients is rarely studied alone and is frequently reported only in a combined category with other less common cancer entities. The data found for melanoma patients were sufficient, however, for estimation purposes. The 21 studies each looked separately at one to nine cancer types. Studies that did not differentiate between different cancer types and their occurrence of cachexia were not considered for this analysis. It should be noted that the individual studies analysed had varying inclusion criteria for the diagnosis of cachexia ranging from weight loss of ≥1% to ≥10%. The consensus definition of cachexia by Evans et al. 32 defined cachexia as a complex metabolic syndrome associated with the underlying illness. In alignment with the consensus definition, a weight loss of at least ≥5% is considered sufficient to diagnose cachexia. A low body mass index (<20 or <18.5) has also been used to define presence of cachexia, often in combination with weight loss of 2-5% or biochemical abnormalities. 33 The data for the 31 047 patients shown in Table 3 originate in the USA, EU, Australia, Canada, and Asia and therefore represent, it is believed, a broad cross section of cancer experience appropriate to characterize the diverse populations in the USA and EU. The proportions of patients in advanced tumour stages or with metastatic disease were generally high in these studies (up to 100% metastatic disease). The frequency of cachexia ranged from 11-74%. The average prevalence of cachexia in each cancer diagnosis was calculated by taking into account all patients with that diagnosis ( Table 4 ). The data were not weighted based on the origin of patients (continent, country, etc.) and so, lacking a Orphan disease status of cancer cachexia: systematic review 
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During the literature research, we also found 10 clinical studies in 4312 patients that asked patients whether they ever lost any weight during the course of their disease. We are showing this data in Table 5 34-43 but did not include it in our analysis, because the inclusion criteria were not sufficient to diagnose cachexia.
Patients at risk
For calculation of the patients at risk in each diagnosis, we categorized Table 4 into four groups of very high, high, middle, and lower risk of cancer cachexia by taking into account the respective 5-year survival rates of the cancer entities. Based on prior clinical experience that the intensity and progression of the cancer disease process is directly related to metabolic disorders responsible for cachexia, it has been assumed that patients with lower 5-year survival rates are more prone to develop cachexia, and therefore, they have been classified as having a higher risk for cachexia development.
Because the 5-year prevalence for each cancer takes into account the cured and sick patients alike, we had to consider this in our analysis and therefore estimated the actual patients at risk to develop cachexia with the help of these four risk groups. To the very high-risk group, we attributed that 80-90% of the patients are at risk, in the high-risk group 50-70%, in the middle-risk group 30-40%, and in the lowerrisk group 20-30% ( Table 4) . Within the four risk groups, we considered the prevalence of cachexia in the patients at risk and again the 5-year survival rate. We were therefore able to weigh the data within these groups (Table 4) .
Consequently, in the very high-risk group, pancreatic cancer patients had the lowest 5-year survival rate and liver cancer the highest prevalence of cachexia in patients at risk. We therefore attributed to both diagnoses that 90% of patients are at risk. Lung cancer had a higher 5-year survival rate and lower cachexia prevalence in patients at risk within this very high-risk group, and so we attributed that 80% of the patients are at risk to develop cachexia. We did the same for the other risk groups as well ( Table 4) .
Number of patients with cancer cachexia
With the attained data, we were able to calculate the estimates for the numbers of cancer patients likely to be suffering from cancer cachexia in the USA (Table 1, Figure 3 ) and in the EU (Table 2, Figure 4) . We estimate that in 2014, in the USA, 527 100 patients suffered from cancer cachexia (of any kind), equalling 16.5 subjects per 10 000 of the total population (USA inhabitants 2014: 318 622 530 5 ). In 2013, in the EU, a total of 800 300 patients suffered from cancer cachexia (of any kind), equalling 15.8 subjects per 10 000 people of the general population (EU inhabitants 2013: 505 170 000 7 ). For each specific cancer type, the absolute numbers of patients suffering of cachexia were lower than 200 000 patients in the USA, or less than 5 per 10 000 people in the EU, and for most types, substantially below those thresholds. Even if a high margin of error of ±30% is applied to the final results, cancer cachexia remains an orphan disease if each cancer type is considered separately, and this was true for all the specific cancer types studied. Given the wide variation in the risk of developing cachexia, we believe it is sensible to look at cancer-specific cachexia rather than considering all cancer cachexia as a single disease. Orphan disease status of cancer cachexia: systematic review 
Discussion
The estimation of the prevalence of cachexia in cancer involves both epidemiological and clinical considerations, requiring both extensive research for current relevant data on multiple cancer types and the development of an approach to integrate that data into meaningful information. Those challenges may be responsible for the lack of published reports on the disease-specific prevalence of cancer cachexia in the USA and EU populations. Recently, Baracos et al. 44 provided data on the prevalence of cachexia in eight cancer diagnoses considering information provided in two original studies with a total of about 3000 patients. In the present study, however, we used data from 21 original reports with a total of over 31 000 patients and assessed 14 cancer diagnoses-the 10 most frequent cancer diagnoses and another 4 cancer types that are frequently associated with cancer cachexia. Furthermore, we calculated the prevalence of cancer cachexia in the general population, giving one the chance to evaluate, whether individual disease related cancer cachexia syndromes should be considered orphan diseases in the USA or EU. We make the case that different cachexia disease types, potentially require individually targeted therapies. Currently, the National Cancer Institute identifies more than 200 different targeted drugs approved to treat over 100 separate cancer types separately.
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Cancer cachexia (in different cancers) is not one and the same general disease. Underlying pathophysiology, genetics, and biochemistry, but also symptoms and prognostic importance are different 46 -both in absolute terms and in their relative impact on disease progression and the patient burden-which is relevant for the development of novel treatment and prevention strategies. Research to this end is only in its infancy. Antecedent cancers are genomically distinct and have unique characteristics associated with the primary tissue affect, thus generally requiring individualized management efforts. Hence, it is reasonable that orphan disease status for cancer cachexia is assessed on the individual cancer type level and not for all cancer cachexia types together.
In the only available original research article on this issue, it has been estimated that cachexia is the immediate or primary cause of death in approximately 30% of cancer patients. 47 Cancer cachexia is also associated with increased length of hospital stay as well as increased overall treatment costs. 48 The possible ways how cachexia can cause death have been the subject of prior publications, which have concluded that in addition to cachexia interfering in the treatment of the cancer itself, it also acts as an indirect contributor to mortality. 49 Future orphan treatments for cachexia might be divided into those that address symptoms and quality of life (palliative) and those that possibly impact mortality (directly addressing the life-limiting disease). 
Limitations
We only have access to summaries of research based on individual patient series, and we therefore had to base our analyses on these data as published. These have somewhat varying definitions of cachexia, so that there is inherent uncertainty around our prevalence estimates. We believe that these variations are likely to be less than 20% above or below our central estimate. Even though we included >30 000 patients in this analysis, which is more than ever shown before, the analysis summarizes only 21 studies, which is due to lack of attention of medicine and frustration about not being able to treat cachexia yet. We used the 5-year prevalence of each cancer type. This estimate is lower than the actual number of all people who ever had the cancer type and who still survive (by excluding those who have carried the diagnosis for more than 5 years). This may be thought to therefore slightly underestimate the prevalence of the respective cancer-type-specific cachexia, but the effect is likely to be small for two reasons.
1.
Patients who have survived more than 5 years include those with cured cancer and those with very slowly progressing disease. These patients will have a lower rate of cachexia development than all comers for that particular cancer type. 2. The cancer patient who develops cachexia has a significantly worse survival than one who does not; therefore, the 5-year prevalence data will have 'lost' some cachexia patients who have on average died earlier. This effect will therefore tend to overestimate the prevalence of cancer cachexia at any point in time, because we have used a constant risk of cachexia development for each cancer type whereas the 5-year prevalence data for each cancer type contains an under-representation of cachexia sufferers who have died and hence are no longer there to be counted in the 5-year prevalence data.
For these reasons, we believe our estimates may actually overestimate rather than underestimate the prevalence of cancer-type-specific cachexia in the USA and in the EU and therefore the risk of misclassifying a condition as an orphan disease when it is not is low. We also make the point that although disease prevalence is used to define orphan disease status, a high mortality condition can have a large impact, because it can affect more patients when measured as disease incidence rather than prevalence. Thus, individual cancer cachexia may be considered low prevalence orphan diseases, but higher incidence high impact disorders, a combination of features that should make them very strong candidates for new prevention and treatment development efforts.
Conclusion
We conclude from this analysis that the absolute number of patients affected by cancer cachexia in each cancer group is lower than the defined thresholds in the USA and EU. Hence, cancer cachexia in each subgroup separately should be considered an orphan disease.
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